Synchronous primary breast invasive carcinoma and breast metastasis from high-grade serous ovarian carcinoma: a case report and literature review - Report - MDSpire

Synchronous primary breast invasive carcinoma and breast metastasis from high-grade serous ovarian carcinoma: a case report and literature review

  • By

  • Jingge Miao

  • Nianqiu Liu

  • Fuhong Gong

  • Jiayi Chen

  • Chenxi Wang

  • Mengping Lin

  • Na Li

  • Yilin Chen

  • Fei Ge

  • Wenlin Chen

  • June 17, 2026

  • 0 min

Share

Concurrent Invasive Breast Carcinoma and Metastatic High-Grade Serous Ovarian Carcinoma

Overview

This report presents a rare case of synchronous invasive breast carcinoma and metastatic high-grade serous ovarian carcinoma. The patient underwent a series of treatments, achieving a partial response and no evidence of disease progression at the last follow-up.

Background

Incorporate statistics or references regarding the rarity of breast metastasis from ovarian carcinoma.

Data Highlights

No numerical data available.

Key Findings

  • The patient was diagnosed with FIGO stage IVB high-grade serous ovarian carcinoma with synchronous primary breast carcinoma.
  • Pathological examination revealed two distinct adenocarcinoma components in the breast: primary invasive carcinoma and metastatic Müllerian carcinoma.
  • Immunohistochemical profiling was essential for distinguishing between the two carcinoma types.
  • The patient received neoadjuvant chemotherapy and achieved a partial response prior to surgical intervention.
  • Molecular testing indicated a pathogenic BRCA mutation, supporting the use of PARP inhibitors in maintenance therapy.

Clinical Implications

Healthcare professionals should be aware of the potential for breast metastasis from ovarian carcinoma, which can mimic primary breast cancer. A thorough immunohistochemical panel is critical for accurate diagnosis, guiding appropriate treatment strategies. Multidisciplinary approaches are recommended for complex cases involving synchronous malignancies.

Conclusion

This case highlights the diagnostic challenges and treatment complexities associated with concurrent breast and ovarian carcinomas. Careful histopathological and immunohistochemical evaluation is vital for optimal patient management.

Related Resources & Content

  1. Frontiers in Oncology, 2026 -- Occult ovarian carcinoid in pregnancy: a case report and literature review
  2. International Journal of Colorectal Disease, 2026 -- Colonic metastasis from breast carcinoma: A case report and systematic review of a rare clinical scenario
  3. Frontiers in Immunology, 2026 -- Follicular T cells in the ovarian cancer immune microenvironment: biological insights and translational implications
  4. Frontiers in Surgery, 2026 -- Port-site metastases after diagnostic laparoscopy in advanced ovarian cancer: a case report and a systematic review of the literature
  5. Immunohistochemistry in the Differential Diagnosis of Triple Negative Breast Carcinoma and High-grade Serous Carcinoma: Old and New Markers - PubMed
  6. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update - PMC
  7. Therapeutic advances and application of PARP inhibitors in breast cancer - PMC
  8. Immunohistochemistry in the Differential Diagnosis of Triple Negative Breast Carcinoma and High-grade Serous Carcinoma: Old and New Markers - PubMed
  9. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update - PMC
  10. Therapeutic advances and application of PARP inhibitors in breast cancer - PMC

Original Source(s)

Related Content